Alcon spin-off prompts Novartis downgrade by Moody’s
Selling off Alcon concentrates business in riskier areas
Original Article: Alcon spin-off prompts Novartis downgrade by Moody’s
More From BioPortfolio on "Alcon spin-off prompts Novartis downgrade by Moody’s"